Calamos Advisors LLC Has $87.32 Million Stock Holdings in Boston Scientific Corporation $BSX

Calamos Advisors LLC decreased its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 21.5% during the 3rd quarter, Holdings Channel reports. The firm owned 894,430 shares of the medical equipment provider’s stock after selling 244,349 shares during the quarter. Calamos Advisors LLC’s holdings in Boston Scientific were worth $87,323,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the business. Norges Bank bought a new position in shares of Boston Scientific during the 2nd quarter worth approximately $2,089,937,000. Edgewood Management LLC acquired a new position in shares of Boston Scientific during the 2nd quarter valued at $746,655,000. Bessemer Group Inc. boosted its stake in Boston Scientific by 14,391.8% during the second quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider’s stock worth $313,618,000 after acquiring an additional 2,899,653 shares in the last quarter. Vanguard Group Inc. boosted its stake in Boston Scientific by 1.9% during the second quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock worth $14,729,575,000 after acquiring an additional 2,545,381 shares in the last quarter. Finally, Bank of Nova Scotia grew its holdings in Boston Scientific by 106.4% in the second quarter. Bank of Nova Scotia now owns 3,025,519 shares of the medical equipment provider’s stock worth $324,971,000 after purchasing an additional 1,559,605 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Stock Up 0.2%

BSX stock opened at $95.98 on Wednesday. The stock has a market cap of $142.28 billion, a P/E ratio of 51.32, a P/E/G ratio of 1.93 and a beta of 0.67. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. The stock’s fifty day simple moving average is $98.36 and its two-hundred day simple moving average is $101.05. Boston Scientific Corporation has a 1-year low of $85.98 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The company had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The business’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same period in the previous year, the business posted $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Erste Group Bank cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Barclays increased their price target on Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a report on Thursday, October 2nd. Royal Bank Of Canada boosted their price objective on Boston Scientific from $125.00 to $130.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Evercore ISI reiterated an “outperform” rating on shares of Boston Scientific in a report on Wednesday, October 22nd. Finally, Truist Financial reduced their price target on shares of Boston Scientific from $130.00 to $120.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Two analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $124.85.

Insider Buying and Selling at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total value of $4,973,500.00. Following the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $17,739,678.74. The trade was a 21.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction on Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. This trade represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 93,095 shares of company stock worth $9,305,450 over the last three months. 0.50% of the stock is currently owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.